Van ECK Associates Corp Cuts Stake in Illumina, Inc. $ILMN

Posted by Brian Himes on Sep 1st, 2026

Van ECK Associates Corp cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 29.2% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 80,373 shares of the life sciences company’s stock after selling 33,102 shares during the period. Van ECK Associates Corp’s holdings in Illumina were worth $14,132,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ILMN. Empowered Funds LLC boosted its stake in Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after acquiring an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Illumina in the 2nd quarter valued at about $621,000. CW Advisors LLC acquired a new stake in shares of Illumina in the 2nd quarter valued at about $275,000. Marshall Wace LLP lifted its position in shares of Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC lifted its position in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Keith A. Meister sold 138,379 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the sale, the director owned 1,033,910 shares of the company’s stock, valued at $236,651,659.90. The trade was a 11.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider directly owned 20,338 shares in the company, valued at $4,067,600. This represents a 2.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,799,688 shares of company stock worth $379,517,231. 2.90% of the stock is owned by corporate insiders.

Illumina Trading Down 0.9%

Shares of NASDAQ ILMN opened at $213.63 on Tuesday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The company has a market cap of $32.26 billion, a price-to-earnings ratio of 39.86, a price-to-earnings-growth ratio of 3.03 and a beta of 1.44. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock’s 50 day simple moving average is $195.10 and its 200 day simple moving average is $156.54.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the firm earned $1.19 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts expect that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Stifel Nicolaus boosted their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus price target of $188.40.

Read Our Latest Stock Analysis on ILMN

Illumina Company Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.